Hämostasestörungen bei Malignomen

H.D. Bruhn; K.-H. Zurborn

doi:10.1055/s-0038-1655333

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 1998; 18(02): 61-69
DOI: 10.1055/s-0038-1655333

Übersichtsarbeit/Review Articles

Schattauer GmbH

Hämostasestörungen bei Malignomen

Pathogenese und therapeutische Konsequenzen

H.D. Bruhn

¹Medizinische Universitätsklinik Kiel

,

K.-H. Zurborn

²Reha-Klinik Ahrenshoop

› Institutsangaben

Abstract

Zusammenfassung

Malignome setzen verstärkt gerinnungsaktive Substanzen frei (Tumorzellenthromboplastine), welche bei Tumorpatienten zu einer erhöhten Frequenz thromboembolischer Erkrankungen führen. Chemotherapie und Strahlentherapie erhöhen das Risiko thromboembolischer Komplikationen durch verstärkten Tumorzellzerfall weiterhin. Das durch Tumorzellenthromboplastine vermehrt entstehende Thrombin ist darüber hinaus als Mitogen bei der Tumorzellproliferation bedeutsam. Vor diesem Hintergrund ist zu verstehen, daß in tierexperimentellen und in klinischen Studien versucht wurde, durch eine gerinnungshemmende Behandlung nicht nur die thromboembolischen Komplikationen, sondern auch das Tumorwachstum zu beeinflussen.

Schlüsselwörter

Tumorzellenthromboplastine - erhöhte Frequenz thromboembolischer Erkrankungen bei Tumorpatienten - Thrombin als Mitogen - Einflüsse einer gerinnungshemmenden Behandlung auf das Tumorwachstum

Volltext

Referenzen

LITERATUR
1 Ambrus JL, Ambrus CM. Blood Coagulation in Neoplastic Disease. In: Onkohämostaseologie. Gastpar H. (ed) Stuttgart-New York: Schattauer; 1976: 167-93.
2 Andoh K, Kubota T, Takada M. et al. Tissue factor activity in leukemic cells. Special reference to disseminated intravascular coagulation. Cancer 1987; 59: 748-54.
3 Avvisati G, Ten Cate JW, Böller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989; i: 122-4.
4 Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71: 511-5.
5 Berger H, Freudenberg N. Todesursachen bei Malignompatienten. Med Welt 1983; 34: 112-8.
6 Bern MM, Lokich JJ, Wallach SR. et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Int Med 1990; 112: 423-8.
7 Bick RL. Alterations of Hemostasis Associated with Malignancy: Etiology, Pathophysiology, Diagnosis and Management. Semin Thromb Hemost 1978; 05: 1-26.
8 Bruhn HD, Zurborn KH. Influence of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. Blut 1983; 46: 85-8.
9 Bruhn HD, Knapp S, Senger H. et al. Auswirkungen einer Strahlen-oder Zytostatikatherapie auf das Hämostasesystem. In: Tilsner V, Matthias FR. (eds) Blutgerinnung und Onkologie. XXXI. Hamburger Symposion über Blutgerinnung; Editiones Roche, Basel: 1988: 171.
10 Bruhn HD, Zurborn KH. Veränderungen des Hämostasesystems bei malignen Erkrankungen und deren klinische Bedeutung. In: Spanuth E. (ed) Malignome und Hämostase. Springer, Berlin; Heidelberg, New York: 1996: 3-15.
11 Chahinian AP, Propert KJ, Ware JH. et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 07: 993-1002.
12 Clarke-Pearson DL, Synan IS, Creasman WT. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Ostet Gynecol 1983; 147: 369-75.
13 Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991; 109: 12-5.
14 Costantini V, Zacharski LR. Fibrin and Cancer. Thromb Haemost 1993; 69: 406-14.
15 de Jong E, Knot EAR, Piket D. et al. Increased Plasminogen Activator Inhibition Levels in Malignancy. Thromb Haemostas 1987; 57: 771-82.
16 Donate MB, Falanga A, Consonni R. et al. Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity. Thromb Haemostas 1990; 64: 11-6.
17 Duffy MJ, O’Grady P. Plasminogen activator and cancer. Perspectives and commentaries. Eur J Cancer Clin Oncol 1984; 20: 577-82.
18 Dvorak HF. Thrombosis and Cancer. Hum Pathol 1987; 18: 275-84.
19 Drapkin RL, Gee TS, Dowling MD. et al. Prophylactic Heparin Therapy in Acute Promyelocytic Leukemia. Cancer 1978; 41: 2484-90.
20 Edwards RL, Silver J, Rickies FR. Human Tumor Procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 205-13.
21 Francis JL. Haemostasis and cancer. Med Lab Sei 1989; 46: 331-46.
22 Gasic GJ, Gasic TB, Galanti N. et al. Platelet-tumor-cell interactions in mice. Int J Cancer 1973; 11: 704-18.
23 Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sei USA 1968; 61: 46-52.
24 Gastpar H. Beeinflussung der Metastasierung durch Hemmung der Thrombozytenaggregation. Beitr Onkol 1982; 13: 290-306.
25 Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. J Lab Clin Med 1930; 16: 369-72.
26 Gordon SG. Tumorprokoagulans, Gerinnung und Fibrinolyse bei malignen Erkrankungen. Hämostaseologie 1985; 05: 160-5.
27 Gralnick HR, Abrell E. Studies of the Procoagulant and Fibrinolytic Activity of Promyelocytes in Acute Promyelocytic Leukaemia. Br J Haematol 1973; 24: 89-99.
28 Guarini A, Gugliotta L, Timoncini C. et al. Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. Scand J Haematol 1985; 34: 152-6.
29 Hagedorn AB, Bowie EJW, Elveback LR, Owen CA. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 1074; 49: 649-53.
30 Hilgard P. Tumorausbreitung und Metastasierung als Indikation für Antikoagulation und Fibrinolysetherapie. In: Gastpar H. (ed) Onkohämostaseologie. Stuttgart-New York: Schattauer; 1976: 107-9.
31 Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Sience 1981; 212: 1270-2.
32 Kutti J. The management of thrombocytosis. Eur J Haematol 1990; 44: 81-8.
33 Kwaan HC, Keer HN. Fibrinolysis in cancer. Semin Thromb Hemost 1990; 16: 230-5.
34 Levine MN, Gent M, Hirsh J. et al. The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer. N Engl J Med 1988; 318: 404-7.
35 Levine MN, Hirsh J, Gent M. et al. Doubleblind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
36 Licciardello JTW, Moake JL, Rudy ChK. et al. Elevated Plasma von Willebrand Factor Levels and Arterial Occlusive Complications Associated with Cisplatin-Based Chemotherapy. Oncology 1985; 42: 296-300.
37 Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79: 368-75.
38 Ludwig H. Anticoagulantien beim fortgeschrittenen Carcinom. Gynäkologe 1974; 07: 204-12.
39 Markus G. The role of haemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Haemost 1984; 10: 61-70.
40 Moore FD, Osteen RT, Karp DD. et al. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 1981; 116: 405-7.
41 Nanninga PB, van Teunenbroek A, Veenhof CHN. et al. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemost 1990; 64: 361-4.
42 Nordstrom M, Lindblad B, Anderson H, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-4.
43 Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastastic potential platelet aggregating activity of cell surface extracts and cell surface sialylation in 10 metastatic variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sei USA 1980; 77: 4336-9.
44 Peuscher FW, Cleton FJ, Armstrong L. et al. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14.
45 Poller L, McKernan A, Thomson JM. et al. Fixed mini-dose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987; 295: 1309-12.
46 Prandoni P, Lensing AWA, Biiller HR. et al. Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer. N Engl J Med 1992; 327: 1128-33.
47 Rasche H, Dietrich M. Hemostatic abnormalities associated with malignant diseases. Europ J Cancer 1977; 13: 1053-64.
48 Rickies FR, Edwards RL. Activation of Blood Coagulation in Cancer: Trousseau’s Syndrome Revisited. Blood 1983; 62: 14-31.
49 Rickies FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992; 11: 237-48.
50 Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulability states: a risky business. J Gen Intern Med 1993; 08: 476-86.
51 Schafer AI. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984; 64: 1-22.
52 Schmidt MB. Die Verbreitungswege der Karzinome und die Beziehungen generalisierter Sarkome zu den leukämischen Neubildungen. Fischer: Jena; 1903
53 Schneider W. Bedeutung von Hämostasestörungen für Diagnostik und Therapie von Tumorkrankheiten. Hämostaseologie 1988; 08: 34-6.
54 Schöndorf TH, Witt I. Protein C in patients under L-asparaginase treatment. In: Witt I. (ed) Protein C-Biochemical and Medical Aspects. Walter de Gruyter; Berlin New York: 1985: 125-34.
55 Südhoff T, Schneider W. Fibrinolytic mechanisms in tumor growth and spreading. Clin Investig 1992; 70: 631-5.
56 Sun NC, McAffee WM, Hum GJ. et al. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 1979; 71: 10-9.
57 Sutor AH, Ritter J. Thrombosen bei Kindern mit akuter lymphatischer Leukämie. Hämostaseologie 1992; 12: 107-15.
58 Tanaka H, Narahara N, Kurabayashi H. et al. Studies on leukemic cell tissue factor. Thromb Res 1989; 53: 535-49.
59 Terranova T, Chiossone F. II fattore coagulazione nell’attecchimento delle cellule neoplastiche immesse in circolo. Boll Soc Ital Biol Sper 1952; 28: 1224-5.
60 Trousseau A. Phlegmasia alba dolens. Clinique médicale de l’hotel-dieu de Paris. The New Sydenham Society; London: 1865: 3-94.
61 Wehmeier A, Schneider W. Megakaryocytes and platelets as the main cause for vascular events in chronic myeloproliferative disease. Hämostaseologie 1996; 16: 151-63.
62 Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous Thrombosis During Multimodal Treatment of Primary Breast Carcinoma. Cancer Treat Rep 1981; 65: 677-9.
63 Zacharski LR, Henderson WG, Rickies FE. et al. Effect of warfarin anticoagulation on survival in carcinoma of lung, colon, head and neck and prostate: final report of VA cooperative study #75. Cancer 1984; 53: 2046-52.
64 Zacharski LR, Costantini V, Wojtukiewicz MZ. Anticoagulants as Cancer Therapy. Sem Oncol 1990; 17: 217-27.
65 Zacharski LR, Donati MB, Rickies FR. Registry of clinical trials of antithrombotic drugs in cancer: second report. Thromb Haemost 1993; 70: 357-60.
66 Zurborn K-H, Duscha H, Gram J, Bruhn HD. Investigations of Coagulation System and Fibrinolysis in Patients with Disseminated Adenocarcinomas and Non-Hodgkin’s Lymphomas. Oncology 1990; 47: 376-80.
67 Zurborn K-H, Gram J, Glander K. et al. Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin’s lymphomas and acute leukemias. Eur J Haematol 1991; 47: 55-9.
68 Zurborn K-H. Hemostasis and hormonal tumor therapy: epidemiology and clinical studies. Gynecol Endocrinol 1993; 07 (Suppl.) 1-5.